Breaking News, Trials & Filings

Adcetris Data Positive in DLBCL

Ph II results lead to expanded trial

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Seattle Genetics has posted updated results from a Phase II clinical trial of Adcetris (brentuximab vedotin) in diffuse large B-cell lymphoma (DLBCL) and other B-cell non-Hodgkin lymphomas. The interim data demonstrated an encouraging activity and tolerability profile in the relapsed and refractory setting. The results showed that single-agent Adcetris induced a 42% objective response rate and manageable safety profile among advanced DLBCL patients, including a high percentage whose disease was...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters